These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27038805)

  • 1. Nuances in the Management of Older People With Multiple Myeloma.
    Pawlyn C; Gay F; Larocca A; Roy V; Ailawadhi S
    Curr Hematol Malig Rep; 2016 Jun; 11(3):241-51. PubMed ID: 27038805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trials investigate first-line thalidomide in multiple myeloma.
    Owen OG
    Lancet Oncol; 2005 Jan; 6(1):6. PubMed ID: 15672486
    [No Abstract]   [Full Text] [Related]  

  • 3. Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
    Boga C; Ozdogu H; Yeral M; Kizilkilic E; Tamer L
    J Support Oncol; 2007 Jun; 5(6):256. PubMed ID: 17624049
    [No Abstract]   [Full Text] [Related]  

  • 4. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
    Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
    Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
    Palumbo A; Gay F
    Hematology Am Soc Hematol Educ Program; 2009; ():566-77. PubMed ID: 20008241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial treatment of transplant-ineligible patients in multiple myeloma.
    Mateos MV; Leleu X; Palumbo A; San Miguel JF
    Expert Rev Hematol; 2014 Feb; 7(1):67-77. PubMed ID: 24308500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elderly patients with multiple myeloma: towards a frailty approach?
    Zweegman S; Engelhardt M; Larocca A;
    Curr Opin Oncol; 2017 Sep; 29(5):315-321. PubMed ID: 28763310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.
    Magalini F; Stella A; Sansoni P
    Intern Emerg Med; 2008 Dec; 3(4):383-5. PubMed ID: 18320148
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
    Ludwig H; Strasser-Weippl K; Schreder M; Zojer N
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix64-70. PubMed ID: 17631598
    [No Abstract]   [Full Text] [Related]  

  • 10. Hematology: Is thalidomide combination a new option for myeloma?
    Palumbo A
    Nat Rev Clin Oncol; 2010 Aug; 7(8):425-6. PubMed ID: 20668477
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When less is more: results Herald 'paradigm shift' in treating newly diagnosed multiple myeloma patients.
    Caffrey MK
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E13. PubMed ID: 25764578
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
    Wasser K; Moehler T; Neben K; Nosas S; Heiss J; Goldschmidt H; Hillengass J; Düber C; Kauczor HU; Delorme S
    Rofo; 2004 Sep; 176(9):1285-95. PubMed ID: 15346264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment option emerges for newly diagnosed multiple myeloma.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Nov; 13(23):10, 12. PubMed ID: 12731484
    [No Abstract]   [Full Text] [Related]  

  • 17. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM; Esteves GV
    Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
    Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
    Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of older patients with multiple myeloma.
    Gay F; Palumbo A
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.